- Home
- ONCO vs ENVB Comparison
ONCO vs ENVB Comparison
Compare ONCO & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCO
- ENVB
- Stock Information
- Founded
- ONCO 2018
- ENVB 1994
- Country
- ONCO United States
- ENVB United States
- Employees
- ONCO N/A
- ENVB N/A
- Industry
- ONCO Biotechnology: Pharmaceutical Preparations
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- ONCO Health Care
- ENVB Health Care
- Exchange
- ONCO Nasdaq
- ENVB Nasdaq
- Market Cap
- ONCO 4.6M
- ENVB 4.1M
- IPO Year
- ONCO 2022
- ENVB N/A
- Fundamental
- Price
- ONCO $0.53
- ENVB $0.35
- Analyst Decision
- ONCO
- ENVB Strong Buy
- Analyst Count
- ONCO 0
- ENVB 1
- Target Price
- ONCO N/A
- ENVB $10.00
- AVG Volume (30 Days)
- ONCO 17.2M
- ENVB 1.0M
- Earning Date
- ONCO 12-10-2024
- ENVB 11-14-2024
- Dividend Yield
- ONCO N/A
- ENVB N/A
- EPS Growth
- ONCO N/A
- ENVB N/A
- EPS
- ONCO N/A
- ENVB N/A
- Revenue
- ONCO $1,870,605.00
- ENVB N/A
- Revenue This Year
- ONCO N/A
- ENVB N/A
- Revenue Next Year
- ONCO N/A
- ENVB N/A
- P/E Ratio
- ONCO N/A
- ENVB N/A
- Revenue Growth
- ONCO N/A
- ENVB N/A
- 52 Week Low
- ONCO $0.32
- ENVB $0.30
- 52 Week High
- ONCO $21.40
- ENVB $2.92
- Technical
- Relative Strength Index (RSI)
- ONCO 41.58
- ENVB 46.61
- Support Level
- ONCO $0.46
- ENVB $0.35
- Resistance Level
- ONCO $0.76
- ENVB $0.39
- Average True Range (ATR)
- ONCO 0.23
- ENVB 0.05
- MACD
- ONCO 0.05
- ENVB -0.00
- Stochastic Oscillator
- ONCO 9.97
- ENVB 19.56
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.